6/7/2013

The FDA has granted St. Jude Medical an investigational device exemption to conduct the first U.S. clinical study of its EnligHTN multielectrode device, which uses radiofrequency energy to disrupt the renal nerves believed to control blood pressure. The trial will involve about 590 patients with drug-resistant hypertension.

Related Summaries